ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
66 872,13
-0,31%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aldeyra Therapeutics Inc (ALDX)

  7. Aldeyra Therapeutics Inc (ALDX) Actualités

ALDX

Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALDX
DateHeureSourceTitreSymboleSociété
08/05/202413h00Business WireAldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
25/04/202413h00Business WireAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayNASDAQ:ALDXAldeyra Therapeutics Inc
18/04/202413h00Business WireAldeyra Therapeutics to Host Research & Development Day on April 25, 2024NASDAQ:ALDXAldeyra Therapeutics Inc
28/03/202412h00Business WireAldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202422h54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202422h48Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202422h40Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202422h06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALDXAldeyra Therapeutics Inc
06/02/202413h00Business WireAldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
29/01/202423h25Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALDXAldeyra Therapeutics Inc
04/01/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
04/01/202413h00Business WireAldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory DiseasesNASDAQ:ALDXAldeyra Therapeutics Inc
19/12/202313h00Business WireAldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic DermatitisNASDAQ:ALDXAldeyra Therapeutics Inc
18/12/202322h01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic DermatitisNASDAQ:ALDXAldeyra Therapeutics Inc
27/11/202322h07Business WireAldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
03/11/202321h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALDXAldeyra Therapeutics Inc
01/11/202312h05Business WireAldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
27/09/202311h45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)NASDAQ:ALDXAldeyra Therapeutics Inc
11/09/202323h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
11/08/202311h45PR Newswire (US)ALDX SHAREHOLDER ALERT: Jakubowitz Law Reminds Aldeyra Shareholders of a Lead Plaintiff Deadline of September 29, 2023NASDAQ:ALDXAldeyra Therapeutics Inc
06/07/202313h00Business WireAldeyra Therapeutics to Participate in SVB Securities Therapeutics ForumNASDAQ:ALDXAldeyra Therapeutics Inc
29/06/202322h24Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALDXAldeyra Therapeutics Inc
29/06/202313h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALDXAldeyra Therapeutics Inc
29/06/202313h00Business WireAldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis PigmentosaNASDAQ:ALDXAldeyra Therapeutics Inc
28/06/202322h01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis PigmentosaNASDAQ:ALDXAldeyra Therapeutics Inc
27/06/202313h00Business WireAldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic CoughNASDAQ:ALDXAldeyra Therapeutics Inc
26/06/202322h01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic CoughNASDAQ:ALDXAldeyra Therapeutics Inc
23/06/202313h00Business WireAldeyra Therapeutics to Join the Russell 2000® and Russell 3000® IndexesNASDAQ:ALDXAldeyra Therapeutics Inc
21/06/202315h34Business WireAldeyra Therapeutics Provides Regulatory Update on ADX-2191NASDAQ:ALDXAldeyra Therapeutics Inc
15/06/202313h00Business WireAldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic ConjunctivitisNASDAQ:ALDXAldeyra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALDX

Dernières Valeurs Consultées

COIN
HDGUSD
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés